EverSource Wealth Advisors’s Whitehawk Therapeutics WHWK Stock Holding History

EverSource Wealth Advisors’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$38	Buy	+10	New	+$42	﹤0.01%	4471

Other funds holding WHWK

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

EverSource Wealth Advisors's WHWK Position: Q3 2026 in Review

EverSource Wealth Advisors opened a new position in Whitehawk Therapeutics (WHWK) in Q3 2026: 10 shares worth $38. The stake represents ﹤0.01% of the portfolio and ranks #4471 among its holdings.

32 funds tracked by Wall St. Rank hold WHWK as of Q3 2026.

EverSource Wealth Advisors held 10 shares of Whitehawk Therapeutics worth $38 as of Q3 2026.
Whitehawk Therapeutics was a new EverSource Wealth Advisors position in Q3 2026.
Whitehawk Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q3 2026, its #4471 holding.
32 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2026.

Based on EverSource Wealth Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.